Close Menu

NEW YORK – Castle Biosciences reported after the close of the market on Tuesday that its second quarter revenues rose 168 percent year over year, thanks largely to strong growth in its melanoma and uveal melanoma test volumes.

For the three months ended June 30, the skin cancer test developer reported total revenues of $10.7 million, up from $4.0 million during the same period a year earlier, and beating the average Wall Street analyst estimate of $7.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Los Angeles Times reports that a case of the novel coronavirus making people ill in China has been reported in the US. 

A bipartisan group of senators has introduced a bill seeking increased funding for certain fields, including synthetic biology, ScienceInsider reports. 

Discover magazine writes that paleoproteomics is increasing being used in archaeology, paleoanthropology, and paleontology, including a recent study of a 6,000-year-old ring. 

In Nucleic Acids Research this week: mutagenic effects of ultraviolet "A" light, post-transcription effects of synonymous mutations, and more.